WASHINGTON (dpa-AFX) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis.
All three dose regimens met the study's primary endpoint, demonstrating significantly greater EASI-75 response rates compared with placebo at Week 16.
Zumilokibart is a half-life extended monoclonal antibody targeting IL-13 and is being developed as a potential treatment for atopic dermatitis.
According to the company, the mid-dose regimen was selected for Phase 3 development based on its efficacy, safety and dosing profile.
The data are being presented as a late breaker at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna.
ABBV's shares closed Tuesday's trading at $263.29, down 1.12%. In overnight trading the stock is at $264.00, up 0.27%.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
